Home > Insider Trading > Filing (0000899243-20-004260)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1492422	Apellis Pharmaceuticals Inc.	APLS	Pharmaceutical Preparations (2834)	271537290

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1657719	O. David Watson	C/O Apellis Pharmaceuticals, Inc 100 Fifth Avenue Waltham MA 02451	General Counsel	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-02-10	6,375	$0.00	40,417	No	4	A	Direct
Common Stock	Disposition	2020-02-10	5,000	$44.50	35,417	No	4	S	Direct
Common Stock	Acquisiton	2020-02-10	7,505	$2.67	42,922	No	4	M	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	S	Direct
No	4	M	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock option (right to buy)	Acquisiton	2020-02-10	38,250	$0.00	38,250	$44.33
Common Stock	Stock option (right to buy)	Disposition	2020-02-10	7,505	$0.00	7,505	$2.67

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
38,250		2030-02-09	No	4	A	Direct
0		2023-12-31	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	10,000	Indirect	See Footnote

Footnotes

Consists of shares of Common Stock issuable under 6,375 restricted stock units ("RSUs") granted pursuant to the Company's 2017 Stock Incentive Plan. Each RSU represents the right to receive one share of Common Stock upon vesting. This RSU was granted on February 10, 2020 and will vest as to 25% of the shares underlying the RSU on the first anniversary of the grant, and 25% of the shares underlying the RSU on each anniversary of the grant thereafter through the fourth anniversary of the grant.
This was a scheduled sale from a 10B5-1 trading plan.
The securities are held by The Watson Education Trust (the "Trust"), for which the reporting person serves as trustee. The reporting person disclaims beneficial ownership over the shares held by the Trust except to the extent of his pecuniary interest therein.
This option was granted on February 10, 2020 and will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the option vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.
This option was granted on January 1, 2014 and has fully vested.